Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 168

1.

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.

Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL Jr, Ho VT, Cutler C, Alyea EP, Antin JH, Soiffer RJ.

Blood. 2004 Sep 1;104(5):1559-64. Epub 2004 May 11.

PMID:
15138163
[PubMed - indexed for MEDLINE]
Free Article
2.

Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.

Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J, Leithaeuser M, Hofmeister N, Junghanss C, Casper J, Hartung G, Holler E, Freund M.

Bone Marrow Transplant. 2005 May;35(10):1003-10.

PMID:
15806135
[PubMed - indexed for MEDLINE]
3.

Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease.

Perales MA, Ishill N, Lomazow WA, Weinstock DM, Papadopoulos EB, Dastigir H, Chiu M, Boulad F, Castro-Malaspina HR, Heller G, Jakubowski AA, O'Reilly RJ, Small TN, Young JW, Kernan NA.

Bone Marrow Transplant. 2007 Sep;40(5):481-6. Epub 2007 Jul 9.

PMID:
17618322
[PubMed - indexed for MEDLINE]
4.

Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.

Wolff D, Wilhelm S, Hahn J, Gentilini C, Hilgendorf I, Steiner B, Kahl C, Junghanss C, Hartung G, Casper J, Uharek L, Holler E, Freund M.

Bone Marrow Transplant. 2006 Sep;38(6):445-51.

PMID:
16951692
[PubMed - indexed for MEDLINE]
5.

Daclizumab for children with corticosteroid refractory graft-versus-host disease.

Teachey DT, Bickert B, Bunin N.

Bone Marrow Transplant. 2006 Jan;37(1):95-9.

PMID:
16247417
[PubMed - indexed for MEDLINE]
6.

Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.

Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F; Phase III Daclizumab Study Group.

Transplantation. 2001 Sep 15;72(5):839-45.

PMID:
11571447
[PubMed - indexed for MEDLINE]
7.

Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.

Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light S.

Blood. 2000 Jan 1;95(1):83-9.

PMID:
10607689
[PubMed - indexed for MEDLINE]
Free Article
8.

Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab.

Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG.

Br J Haematol. 2001 Mar;112(3):820-3.

PMID:
11260089
[PubMed - indexed for MEDLINE]
9.

Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.

Rao K, Rao A, Karlsson H, Jagani M, Veys P, Amrolia PJ.

J Pediatr Hematol Oncol. 2009 Jun;31(6):456-61. doi: 10.1097/MPH.0b013e31819daf60.

PMID:
19648797
[PubMed - indexed for MEDLINE]
10.

Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.

Uberti JP, Ayash L, Braun T, Reynolds C, Silver S, Ratanatharathorn V.

Bone Marrow Transplant. 2004 Sep;34(5):425-31.

PMID:
15273705
[PubMed - indexed for MEDLINE]
11.

Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.

Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D, Donohue T, Shalabi R, Carvallo C, Barrett AJ, Geller N, Childs R.

Br J Haematol. 2004 Mar;124(6):777-86.

PMID:
15009066
[PubMed - indexed for MEDLINE]
12.

Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.

Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP.

Liver Transpl. 2005 Jan;11(1):61-7.

PMID:
15690537
[PubMed - indexed for MEDLINE]
Free Article
13.

Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.

Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Storb R, Appelbaum FR, Martin PJ.

Blood. 2002 Jul 1;100(1):48-51.

PMID:
12070007
[PubMed - indexed for MEDLINE]
Free Article
14.

Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.

Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Horton C, Atra A, Ortin M, Rudin C, Goyal S, Sankpal S, Meller S, Pinkerton CR, Mehta J, Singhal S.

Bone Marrow Transplant. 2003 Jul;32(2):165-70.

PMID:
12838281
[PubMed - indexed for MEDLINE]
15.

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group.

Lancet Oncol. 2009 Sep;10(9):855-64. doi: 10.1016/S1470-2045(09)70225-6. Epub 2009 Aug 18.

PMID:
19695955
[PubMed - indexed for MEDLINE]
16.

Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study.

Cahn JY, Bordigoni P, Tiberghien P, Milpied N, Brion A, Widjenes J, Lioure B, Michel G, Burdach S, Kolb HJ, et al.

Transplantation. 1995 Nov 15;60(9):939-42.

PMID:
7491697
[PubMed - indexed for MEDLINE]
17.

Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation.

Martin PJ, Nelson BJ, Appelbaum FR, Anasetti C, Deeg HJ, Hansen JA, McDonald GB, Nash RA, Sullivan KM, Witherspoon RP, Scannon PJ, Friedmann N, Storb R.

Blood. 1996 Aug 1;88(3):824-30.

PMID:
8704237
[PubMed - indexed for MEDLINE]
Free Article
18.

Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10)

Hervé P, Wijdenes J, Bergerat JP, Bordigoni P, Milpied N, Cahn JY, Clément C, Béliard R, Morel-Fourrier B, Racadot E, et al.

Blood. 1990 Feb 15;75(4):1017-23.

PMID:
2136244
[PubMed - indexed for MEDLINE]
Free Article
19.

Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.

Bay JO, Dhédin N, Goerner M, Vannier JP, Marie-Cardine A, Stamatoullas A, Jouet JP, Yakoub-Agha I, Tabrizi R, Faucher C, Diez-Martin JL, Nunez G, Parody R, Milpied N, Espérou H, Garban F, Galambrun C, Kwiatkovski F, Darlavoix I, Zinaï A, Fischer A, Michallet M, Vernant JP.

Transplantation. 2005 Sep 27;80(6):782-8.

PMID:
16210965
[PubMed - indexed for MEDLINE]
20.

Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.

Fang J, Hu C, Hong M, Wu Q, You Y, Zhong Z, Li W, Zou P, Hu Y, Xia L.

Biol Blood Marrow Transplant. 2012 May;18(5):754-62. doi: 10.1016/j.bbmt.2011.09.005. Epub 2011 Sep 29.

PMID:
21963619
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk